Lynparza vs Tagrisso
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Lynparza | US Tagrisso | |
|---|---|---|
| Generic name | olaparib | osimertinib |
| Drug class | PARP Inhibitor | EGFR Tyrosine Kinase Inhibitor |
| Treats | Ovarian, breast, prostate, and pancreatic cancers | EGFR-positive non-small cell lung cancer |
| Category | Oncology | Oncology |
| Manufacturer | AstraZeneca | AstraZeneca |
| Year approved | 2014 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Nausea, Fatigue, Low blood counts, Risk of blood cancers (MDS/AML) | Diarrhea, Rash, Dry skin, Lung inflammation |
Frequently asked questions
Is Lynparza or Tagrisso better?
Neither is universally "better." Lynparza (olaparib) and Tagrisso (osimertinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Lynparza and Tagrisso?
Lynparza is a PARP Inhibitor made by AstraZeneca, while Tagrisso is a EGFR Tyrosine Kinase Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Lynparza has the larger estimated TV advertising budget of the two.